NRx deploys robotic TMS system in clinics

• NRx Pharmaceuticals (NASDAQ:NRXP) subsidiary HOPE Therapeutics began deploying Zeta Surgical’s FDA-cleared robotic TMS system in Florida clinics.
• The AI-driven platform adjusts TMS coil positioning with submillimeter precision during treatment.
• The rollout supports NRx’s SPARC-TMS Phase 2/3 trial combining NRX-101 with robotic TMS.

NRx Pharmaceuticals (NASDAQ:NRXP) announced that its subsidiary HOPE Therapeutics has started deploying Zeta Surgical’s FDA-cleared robotic TMS system at Florida clinics.

HOPE Therapeutics became the first Interventional Psychiatry network to use the Zeta TMS Robotic System after completing clinical orientation and training at Zeta Surgical’s Boston headquarters.

The robotic platform uses artificial intelligence to adjust the TMS coil position in real time with submillimeter precision and extends the Zeta TMS Navigation System that HOPE began using in June 2026.

The deployment supports SPARC-TMS, NRx Pharmaceuticals’ FDA-approved Phase 2/3 trial evaluating NRX-101 combined with robotic TMS across an academic hospital, HOPE clinics, and two military treatment facilities.

NRx said it was selected by DARPA as prime contractor for the program, subject to completion of contracting requirements, and will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference.